TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques
- PMID: 22041305
- PMCID: PMC3258186
- DOI: 10.1016/j.vaccine.2011.10.043
TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques
Abstract
Adjuvant plays an important role in increasing and directing vaccine-induced immune responses. In a previous study, we found that a mucosal SIV vaccine using a combination of IL-15 and TLR agonists as adjuvant mediated partial protection against SIVmac251 rectal challenge, whereas neither IL-15 nor TLR agonists alone as an adjuvant impacted the plasma viral loads. In this study, dissociation of CD4(+) T cell preservation with viral loads was observed in the animals vaccinated with adjuvants. Significantly higher levels of memory CD4(+) T cell numbers were preserved after SIVmac251 infection in the colons of the animals vaccinated with vaccine containing any of these adjuvants compared to no adjuvant. When we measured the viral-specific CD8(+) tetramer responses in the colon lamina propria, we found significantly higher levels of gag, tat, and pol epitope tetramer(+) T cell responses in these animals compared to ones without adjuvant, even if some of the animals had similarly high viral loads. Furthermore, this CD4(+) T preservation was positively correlated with increased levels of gag and Tat, but not pol tetramer(+) T cell responses, and inversely correlated with beta-chemokine expression. The pre-challenged APOBEC3G expression level, which has previously been shown inversely associated with viral loads, was further found positively correlated with CD4(+) T cell number preservation. Overall, these data highlight one unrecognized role of adjuvant in HIV vaccine development, and show that vaccines can produce a surprising discordance between CD4(+) T cell levels and SIV viral load.
Published by Elsevier Ltd.
Figures
Similar articles
-
DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.AIDS Res Hum Retroviruses. 2008 Mar;24(3):505-19. doi: 10.1089/aid.2007.0191. AIDS Res Hum Retroviruses. 2008. PMID: 18373436 Free PMC article.
-
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.J Virol. 2017 Jan 31;91(4):e01844-16. doi: 10.1128/JVI.01844-16. Print 2017 Feb 15. J Virol. 2017. PMID: 27928002 Free PMC article.
-
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11. J Virol. 2014. PMID: 24920805 Free PMC article.
-
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.Proc Natl Acad Sci U S A. 2010 May 25;107(21):9843-8. doi: 10.1073/pnas.0911932107. Epub 2010 May 10. Proc Natl Acad Sci U S A. 2010. PMID: 20457926 Free PMC article.
-
The role of immunity in protection from mucosal SIV infection in macaques.Oral Dis. 2002;8 Suppl 2:63-8. doi: 10.1034/j.1601-0825.2002.00014.x. Oral Dis. 2002. PMID: 12164663 Review.
Cited by
-
Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.J Clin Invest. 2019 Mar 1;129(3):1314-1328. doi: 10.1172/JCI122110. Epub 2019 Feb 18. J Clin Invest. 2019. PMID: 30776026 Free PMC article.
-
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.Clin Immunol. 2014 Aug;153(2):308-22. doi: 10.1016/j.clim.2014.05.008. Epub 2014 Jun 4. Clin Immunol. 2014. PMID: 24907411 Free PMC article.
-
Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.Front Immunol. 2024 May 21;15:1386243. doi: 10.3389/fimmu.2024.1386243. eCollection 2024. Front Immunol. 2024. PMID: 38835757 Free PMC article.
-
Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.PLoS Pathog. 2017 May 12;13(5):e1006395. doi: 10.1371/journal.ppat.1006395. eCollection 2017 May. PLoS Pathog. 2017. PMID: 28498847 Free PMC article.
-
Innate protection against intrarectal SIV acquisition by a live SHIV vaccine.JCI Insight. 2024 May 21;9(12):e175800. doi: 10.1172/jci.insight.175800. JCI Insight. 2024. PMID: 38912579 Free PMC article.
References
-
- Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al. Gastrointestinal Tract as a Major Site of CD4+ T Cell Depletion and Viral Replication in SIV Infection. Science. 1998;280:427–31. - PubMed
-
- Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003 Nov;77(21):11708–17. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials